Myles D. Greenberg, M.D.

Myles is a graduate of the University of Pennsylvania School of Engineering and Applied Science, Yale University School of Medicine, and Harvard Business School. He completed residency training in emergency medicine at the University of Pittsburgh and is board certified by the American Board of Emergency Medicine. After residency, Myles served on the faculty of the Beth Israel Deaconess Medical Center / Harvard Medical School as Assistant Clinical Director of the emergency department.

Prior to joining CHL Medical Partners in 2004, Myles was a Senior Principal at A. M. Pappas & Associates (now Pappas Ventures) where he led six investments, serving on the boards of four: Angiomics, Inc., Dynogen Pharmaceuticals, Inc., FlowCardia, Inc., and NuVasive, Inc. Myles currently serves on the board of five CHL Medical Partners portfolio companies, IVREA Pharmaceuticals, Inc., Millennium Pharmacy Systems, Inc., Oculir, Inc., Oriel Therapeutics, Inc. and ParinGenix, Inc., where he serves as Chairman.

Myles can be reached at mgreenberg@chlmedical.com.